CanSino looks for next growth shot in ‘life after Covid’
The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades Key Takeaways: CanSino logged sizable asset impairments for its…
Meningitis vaccine
